Barrier to DAA‐treatment uptakea
Patient refusal	9 (31%)
No liver fibrosis	7 (24%)
Infrequent visit attendance	6 (21%)
Severe comorbidity	5 (17%)
Insufficient adherence expected	3 (10%)
Physician‐reported risk of onward HCV transmissionb	1 (3%)
Additional data collection form not returned	9 (31%)

Data obtained via a questionnaire by the treating physician (December 2020). DAA, direct‐acting antivirals; HCV, hepatitis C virus.

^aFive most frequent barriers mentioned. Multiple barriers per individual are possible.

^bRisk of onward sexual transmission and/or onward transmission through drug use.